| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Beam Therapeutics Inc. | 10%+ Owner | Common Stock | 2.92M | $77.2M | $26.42 | Jun 30, 2021 | Indirect |
| Beam Therapeutics Inc. | 10%+ Owner | Common Stock | 28.1K | $743K | $26.42 | Jun 30, 2021 | Direct |
| Lyell Immunopharma, Inc. | 10%+ Owner | Common Stock | 910K | $364K | $0.40 | Jul 25, 2025 | By ARCH Venture Fund IX, L.P. |
| Lyell Immunopharma, Inc. | 10%+ Owner | Common Stock | 910K | $364K | $0.40 | Jul 25, 2025 | By ARCH Venture Fund IX Overage, L.P. |
| Vir Biotechnology, Inc. | 10%+ Owner | Common Stock | 61.2K | $93.6K | $1.53 | Sep 6, 2022 | Indirect |
| Vir Biotechnology, Inc. | 10%+ Owner | Common Stock | 30.6K | $46.8K | $1.53 | Sep 6, 2022 | Direct |